[{"orgOrder":0,"company":"Orbit Discovery","sponsor":"Evergreen Theragnostics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Orbit Discovery","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orbit Discovery \/ Evergreen Theragnostics","highestDevelopmentStatusID":"4","companyTruncated":"Orbit Discovery \/ Evergreen Theragnostics"},{"orgOrder":0,"company":"Orbit Discovery","sponsor":"Endevica Bio","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery","graph3":"Orbit Discovery","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orbit Discovery \/ Endevica Bio","highestDevelopmentStatusID":"2","companyTruncated":"Orbit Discovery \/ Endevica Bio"},{"orgOrder":0,"company":"Orbit Discovery","sponsor":"Evergreen Discovery","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Orbit Discovery","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Orbit Discovery \/ Evergreen Discovery","highestDevelopmentStatusID":"4","companyTruncated":"Orbit Discovery \/ Evergreen Discovery"},{"orgOrder":0,"company":"Orbit Discovery","sponsor":"Oranomed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Orbit Discovery","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Orbit Discovery \/ Oranomed","highestDevelopmentStatusID":"4","companyTruncated":"Orbit Discovery \/ Oranomed"}]

Find Clinical Drug Pipeline Developments & Deals by Orbit Discovery

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Peptide-Based Therapeutics Summit
                          Not Confirmed
                          Peptide-Based Therapeutics Summit
                          Not Confirmed

                          Details : The expanded collaboration will leverage Orbit’s proprietary screening platform to identify and optimize peptide candidates, combined with Evergreen’s expertise in radiopharmaceutical development.

                          Product Name : Undisclosed

                          Product Type : Peptide

                          Upfront Cash : Undisclosed

                          December 03, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Evergreen Theragnostics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : Under the terms of the collaboration, Orbit will deploy its bead-based peptide display engine to discover peptide leads specific to targets related to specific tumours.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          November 09, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Sponsor : Oranomed

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : The collaboration aims to identify specific cell targeting peptides and advance the development of novel radiopharmaceuticals. The collaboration will leverage Orbit’s peptide display technologies to find peptide leads specific to tumour related targets...

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          March 04, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Sponsor : Evergreen Discovery

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          04

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : The collaboration aims to accelerate Endevica’s development of advanced GPCR-targeting therapeutics on receptor sets both novel and complimentary to its lead compound to creat first-in-class therapeutics for cachexia caused by cancer and other chronic ...

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          January 02, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Discovery

                          Sponsor : Endevica Bio

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank